Apellis Pharmaceuticals to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 11:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 11:30 a.m. ET. The event will be held virtually, featuring a fireside chat with Cedric Francois, M.D., Ph.D., co-founder and CEO. The presentation can be accessed via live webcast on the company’s website, with a replay available for 90 days. Apellis is focused on developing targeted C3 therapies for serious diseases affected by the complement cascade, including conditions in hematology, ophthalmology, and nephrology.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was +2.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 11:30 a.m. ET. The conference will be held in a virtual meeting format.
Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat. The event will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.
Investor Contact:
Sam Martin / Maghan Meyers
Argot Partners
sam@argotpartners.com / maghan@argotpartners.com
212.600.1902
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.